Articles by William Looney

Five Policies for Pharma's Big 50

May 1, 2010
By: William Looney

Cash-rich Big Pharmas are hedging their bets to cover both segments under the rubric of "diversification." If it sticks to the wall, then buy it.

A Challenging Harvest

Apr 1, 2010
By: William Looney

Success in this harsh climate depends on seeing business through the eye of the customer

All Things to All People?

Mar 1, 2010
By: William Looney

Is it possible to remain commercially relevant just as a developer and distributor of drugs? Are there equivalent profits in a larger set of commitments?

The New Merck's Move on Emerging Markets

Mar 1, 2010
By: William Looney

Can the combination with Schering-Plough transform the company from an also-ran to a contender in the big push for market share in the developing world?

Palpitations in the Heart of US Biotech

Feb 3, 2010
By: William Looney

California's biotech industry takes its own pulse in a new survey that tracks how the state is doing in serving as the nation's medicine cabinet and avatar of drug innovation.

Brand of the Year: Avastin

on a Drug that Keeps on Giving
Feb 1, 2010
By: William Looney

As Genentech's Avastin continues to mature and spread its branches, the company is looking for high profits on the back end.

Assets for Advantage

This month, we include a dose of "change management," along with quantitative analysis of the future sales force and a look at the junction of science and serendipity
Feb 1, 2010
By: William Looney

Innovation won't happen until the industry is ready to sit down and make a big change.